Trial Profile
Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 May 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Carboplatin (Primary)
- Indications Ependymoma
- Focus Therapeutic Use
- 15 May 2021 Status changed from recruiting to completed.
- 18 Jun 2020 Planned End Date changed from 1 Jul 2022 to 1 Jul 2024.
- 06 Jul 2019 Planned End Date changed from 1 Jul 2020 to 1 Jul 2022.